Table 2.
Association of admission sex and mineralocorticoid hormone metabolite levels with short- and long-term all-cause mortality in males with CAP
| Men (N = 172) | All-cause mortality timepoint | |||||
|---|---|---|---|---|---|---|
| 30 days | 3 years | 6 years | ||||
| HR (95%CI) | p value | HR (95%CI) | p value | HR (95%CI) | p value | |
| Progesterone | ||||||
| Cox regression analyses | 0.66 (95%CI 0.11–3.83) | p = 0.643 | 0.66 (95%CI 0.34–1.31) | p = 0.239 | 0.69 (95%CI 0.40–1.18) | p = 0.178 |
| 17-OH-Progesterone | ||||||
| Cox regression analyses | 0.72 (95%CI 0.35–1.48) | p = 0.369 | 0.66 (95%CI 0.47–0.92) | p = 0.015 | 0.72 (95%CI 0.54–0.97) | p = 0.029 |
| Aldosterone | ||||||
| Cox regression analyses | 1.91 (95%CI 0.55–6.63) | p = 0.310 | 1.25 (95%CI 0.74–2.12) | p = 0.410 | 0.89 (95%CI 0.59–1.33) | p = 0.565 |
| DHEA | ||||||
| Cox regression analyses | 0.16 (95%CI 0.01–3.79) | p = 0.255 | 0.67 (95%CI 0.35–1.27) | p = 0.221 | ||
| DHEA-S | ||||||
| Cox regression analyses | 0.57 (95%CI 0.01–25.17) | p = 0.768 | 0.69 (95%CI 0.20–2.42) | p = 0.562 | 0.55 (95%CI 0.18–1.67) | p = 0.293 |
| Androstenedione | ||||||
| Cox regression analyses | 5.46 (95%CI 0.85–35.12) | p = 0.074 | 0.59 (95%CI 0.34–0.99) | p = 0.049 | 0.65 (95%CI 0.40–1.05) | p = 0.081 |
| Testosterone | ||||||
| Cox regression analyses | 0.69 (95%CI 0.16–2.94) | p = 0.613 | 1.36 (95%CI 0.73–2.52) | p = 0.328 | 1.04 (95%CI 0.64–1.72) | p = 0.865 |
| Dihydrotestosterone | ||||||
| Cox regression analyses | 6.08 (95%CI 0.15–254.59) | p = 0.344 | 2.0 (95%CI 0.64–6.27) | p = 0.236 | 2.84 (95%CI 1.15–6.99) | p = 0.023 |
Data for multivariate Cox regression models are presented as HR (95% CI), p value; p values are considered statistically significant at p < 0.05. Bold values indicate statistical significance. All hormone metabolite levels were log-transformed and thus the HR corresponds to a 10-fold increase in these levels. CI confidence interval, DHEA dehydroepiandrosterone, DHEA-S dehydroepiandrosterone sulfate, HR hazard ratio
The multivariate model is adjusted for age and comorbidities (coronary artery disease, cerebrovascular disease, chronic kidney disease, neoplastic disease)